Updates in acute graft‐versus‐host disease: From novel pathogenic mechanisms to emerging therapeutic targets
British Journal of Haematology · 01.11.2026
DOI: 10.1111/bjh.70877 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 01.11.2026. Verfasst von Hazim Khatib und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Faculty of Medicine, Medical Center-University of Freiburg, Albert Ludwigs University (ALU), Freiburg, Germany. Die Arbeit nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Acute graft‐versus‐host disease (aGVHD) remains a major complication following allogeneic haematopoietic stem cell transplantation (allo‐HSCT), representing a leading cause of non‐relapse mortality (NRM) and significant morbidity despite decades of intensive research. Its pathogenesis involves human leucocyte antigen (HLA) mismatch between donor and recipient and is initiated by conditioning‐induced tissue damage that triggers alloreactive donor T‐cell activation. Beyond classical immunological mechanisms, the intestinal microbiome and microbiome‐derived metabolites have emerged as fundamental modulators of disease initiation and progression. Significant advances have been made in staging and risk stratification, with novel scoring systems integrating clinical parameters and biological biomarkers to more accurately predict treatment response and overall outcome. In the treatment of aGVHD, the last decade has witnessed considerable progress, most notably the approval of ruxolitinib, which has fundamentally changed the management landscape of steroid‐refractory aGVHD (SR‐aGVHD). Intestinal aGVHD, which carries the highest mortality among disease manifestations, remains a particularly challenging entity. Notably, the enteroendocrine system has recently gained attention as a pathogenic contributor, with early‐phase trials exploring the therapeutic potential of exogenous hormone administration. In this review, we discuss both well‐established and emerging evidence on the pathogenesis, staging and risk stratification and treatment of aGVHD, with particular focus on novel therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine I, Faculty of Medicine, Medical Center-University of Freiburg, Albert Ludwigs University (ALU), Freiburg, Germany.
- Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
- German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Signalling Research Centre CIBSS-Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany.
ORCID-Profile: Robert Zeiser
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Khatib, H., & Zeiser, R. (2026). Updates in acute graft‐versus‐host disease: From novel pathogenic mechanisms to emerging therapeutic targets. British Journal of Haematology. https://doi.org/10.1111/bjh.70877
Vancouver
Khatib H, Zeiser R. Updates in acute graft‐versus‐host disease: From novel pathogenic mechanisms to emerging therapeutic targets. British Journal of Haematology. 2026. doi:10.1111/bjh.70877
BibTeX
@article{Khatib2026,
author = {Khatib, Hazim and Zeiser, Robert},
title = {Updates in acute graft‐versus‐host disease: From novel pathogenic mechanisms to emerging therapeutic targets},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70877}
}
EUVIMED